Moreover, although previous clinical studies showed that the use of bFGF alone for repairing traumatic perforations did not cause reperforation or acquired cholesteatoma in the long-term [20], clinical studies of bFGF combined with biological scaffold obtained similar findings [13–17]. The gene discussed is FGF2; the disease is cholesteatoma.